How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia

Abstract Collecting self-reported data on adherence to highly active antiretroviral therapy (HAART) can be complicated by patients’ reluctance to report poor adherence. The timeliness with which patients attend visits might be a useful alternative to estimate medication adherence. Among Kenyan and Zambian women receiving twice daily HAART, we examined the relationship between self-reported pill taking and timeliness attending scheduled visits. We analyzed data from 566 Kenyan and Zambian women enrolled in a prospective 48-week HAART-response study. At each scheduled clinic visit, women reported doses missed over the preceding week. Self-reported adherence was calculated by summing the total number of doses reported taken and dividing by the total number of doses asked about at the visit attended. A participant's adherence to scheduled study visits was defined as “on time” if she arrived early or within three days, “moderately late” if she was four–seven days late, and “extremely late/missed” if she was more than eight days late or missed the visit altogether. Self-reported adherence was <95% for 29 (10%) of 288 women who were late for at least one study visit vs. 3 (1%) of 278 who were never late for a study visit (odds ratios [OR] 10.3; 95% confidence intervals [95% CI] 2.9, 42.8). Fifty-one (18%) of 285 women who were ever late for a study visit experienced virologic failure vs. 32 (12%) of 278 women who were never late for a study visit (OR 1.7; 95% CI 1.01, 2.8). A multivariate logistic regression model controlling for self-reported adherence found that being extremely late for a visit was associated with virologic failure (OR 2.0; 95% CI 1.2, 3.4). Timeliness to scheduled visits was associated with self-reported adherence to HAART and with risk for virologic failure. Timeliness to scheduled clinic visits can be used as an objective proxy for self-reported adherence and ultimately for risk of virologic failure.

[1]  J. Nachega,et al.  Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy , 2008, PLoS medicine.

[2]  F. Oort,et al.  Self-Reported Adherence to Antiretroviral Therapy for HIV-1 Infection and Virologic Treatment Response: A Meta-Analysis , 2005, Journal of acquired immune deficiency syndromes.

[3]  David R Bangsberg,et al.  Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. , 2008, The Journal of infectious diseases.

[4]  D. Bangsberg,et al.  Adherence is not a barrier to successful antiretroviral therapy in South Africa , 2003, AIDS.

[5]  Jim Todd,et al.  Patterns of Individual and Population-Level Adherence to Antiretroviral Therapy and Risk Factors for Poor Adherence in the First Year of the DART Trial in Uganda and Zimbabwe , 2008, Journal of acquired immune deficiency syndromes.

[6]  M. Chesney,et al.  The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  T. Quinn,et al.  A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. , 2006, The Lancet. Infectious diseases.

[8]  Aniset Kamanga,et al.  Predictors of Adherence to Antiretroviral Therapy in Rural Zambia , 2008, Journal of acquired immune deficiency syndromes.

[9]  D. Bangsberg,et al.  Multiple Validated Measures of Adherence Indicate High Levels of Adherence to Generic HIV Antiretroviral Therapy in a Resource-Limited Setting , 2004, Journal of acquired immune deficiency syndromes.

[10]  F. Liégeois,et al.  The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study , 2002, AIDS.

[11]  B. Chi,et al.  Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia , 2008, AIDS care.

[12]  Joel E Gallant,et al.  Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  L. Hirschhorn,et al.  The CASE adherence index: A novel method for measuring adherence to antiretroviral therapy , 2006, AIDS care.

[14]  I. Buchan,et al.  Adherence to HAART : A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators , 2006 .

[15]  Sung-Han Kim,et al.  Self-reported reasons among HIV-infected patients for missing clinic appointments , 2008, International journal of STD & AIDS.

[16]  D. Bangsberg,et al.  Doubts about DOT: antiretroviral therapy for resource‐poor countries , 2003, AIDS.

[17]  K. Buchacz,et al.  Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda , 2006, The Lancet.

[18]  J. Arnsten,et al.  Practical and Conceptual Challenges in Measuring Antiretroviral Adherence , 2006, Journal of acquired immune deficiency syndromes.

[19]  J. Stringer,et al.  Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine: A Multi-country, Prospective Cohort Study , 2010, PLoS medicine.

[20]  M. Mimiaga,et al.  Nonadherence to medical appointments is associated with increased plasma HIV RNA and decreased CD4 cell counts in a community-based HIV primary care clinic , 2005, AIDS care.

[21]  N. McGrath,et al.  Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi , 2008, The Lancet.

[22]  M. Wainberg,et al.  Public health implications of antiretroviral therapy and HIV drug resistance. , 1998, JAMA.

[23]  B. Chi,et al.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. , 2006, JAMA.

[24]  G. Guyatt,et al.  Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. , 2006, JAMA.

[25]  D. Hamer,et al.  No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. , 2005, AIDS.

[26]  A. Wu,et al.  Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence , 2005, AIDS care.

[27]  D. Jasinski,et al.  Highly active antiretroviral therapy outcomes in a primary care clinic , 2003, AIDS care.

[28]  C. Orrell.  Antiretroviral adherence in a resource-poor setting , 2005, Current HIV/AIDS reports.

[29]  R. Gross,et al.  Antiretroviral Failure Despite High Levels of Adherence: Discordant Adherence-Response Relationship in Botswana , 2008, Journal of acquired immune deficiency syndromes.

[30]  E. Delaporte,et al.  Adherence to Antiretroviral Therapy Assessed by Drug Level Monitoring and Self-Report in Cameroon , 2008, Journal of acquired immune deficiency syndromes.

[31]  Adherence and HIV Drug Resistance , 2004, HIV clinical trials.

[32]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.